GRCL
Gracell Biotechnologies Inc.
485.20$
-2.8%
vs. previous close
Closing price · As of: Aug 13, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 84.5% | 93.1% | 92.4% | 91.9% | 91.5% | 91.1% | 91.6% | 90.8% | 90.3% | 89.9% | 90.5% | 93.9% | |
| 78.2% | 90.4% | 89.4% | 88.9% | 88.8% | 83.9% | 80.8% | 77.9% | 87.8% | 86.4% | -11.5% | 88.8% | |
| 80.1% | 90.8% | 89.6% | 89.1% | 89.0% | 87.7% | 89.9% | 88.6% | 88.0% | 86.7% | 86.2% | 90.4% | |
| 3.2% | 1.3% | – | – | 2.0% | 2.1% | 0.5% | – | 1.6% | 1.8% | 0.0% | – | |
| 0.7% | 0.3% | – | – | 0.4% | 0.4% | 1.1% | – | -1.6% | -1.8% | 0.0% | – | |
| 12.3% | 6.0% | 7.1% | 7.1% | 7.4% | 7.5% | 6.9% | 8.2% | 8.7% | – | – | 5.7% | |
| 15.1% | 8.1% | 9.6% | 10.1% | 11.3% | 13.5% | 15.0% | 16.9% | 16.9% | 17.9% | 17.5% | 14.2% | |
| 9.7% | 5.1% | 5.8% | 6.2% | 7.5% | 9.7% | 11.4% | 13.4% | 13.3% | 14.4% | 14.1% | 12.1% | |
| 5.3% | 3.2% | 3.3% | 3.5% | 4.2% | 5.4% | 6.4% | 8.0% | 7.8% | 9.3% | 8.4% | 4.3% | |
| – | – | – | – | 3.0% | 3.2% | – | – | – | – | – | – | |
| 5.4% | 2.2% | 2.4% | 2.5% | 2.6% | 2.8% | 2.8% | 2.6% | 2.8% | 2.8% | 2.9% | 1.8% | |
| 84.9% | 91.9% | 90.4% | 89.9% | 88.7% | 86.5% | 85.0% | 83.1% | 83.1% | 82.1% | 82.5% | 85.8% | |
| -58.5% | -27.8% | -33.2% | -40.5% | -49.4% | -60.8% | -69.6% | -81.3% | -98.1% | -120.6% | -139.6% | -105.4% | |
| 6.3% | 0.5% | 0.6% | 0.6% | 3.2% | 0.7% | 0.7% | 0.7% | 4.1% | 0.9% | 1.0% | 0.9% |
Data as of: August 13, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.